Lye Mun Tho

5.5k total citations · 1 hit paper
33 papers, 1.6k citations indexed

About

Lye Mun Tho is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Lye Mun Tho has authored 33 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 5 papers in Surgery. Recurrent topics in Lye Mun Tho's work include Lung Cancer Treatments and Mutations (17 papers), Gastric Cancer Management and Outcomes (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). Lye Mun Tho is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Gastric Cancer Management and Outcomes (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). Lye Mun Tho collaborates with scholars based in Malaysia, United Kingdom and Singapore. Lye Mun Tho's co-authors include David A. Gillespie, Naihan Xu, A. McDonald, Ross Carruthers, Elaine McCartney, Jennifer R. Brown, Alexander McDonald, Christina Yap, D. Ferry and Hanlim Moon and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Oncogene.

In The Last Decade

Lye Mun Tho

31 papers receiving 1.6k citations

Hit Papers

The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signalin... 2010 2026 2015 2020 2010 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lye Mun Tho Malaysia 15 869 780 315 271 173 33 1.6k
Dolores Gallardo‐Rincón Mexico 18 494 0.6× 524 0.7× 275 0.9× 219 0.8× 165 1.0× 49 1.3k
Massimiliano D’Aiuto Italy 22 449 0.5× 563 0.7× 275 0.9× 453 1.7× 163 0.9× 78 1.4k
Guoliang Xu China 17 602 0.7× 266 0.3× 184 0.6× 116 0.4× 216 1.2× 34 1.5k
Ou Huang China 24 497 0.6× 892 1.1× 228 0.7× 818 3.0× 184 1.1× 100 1.8k
Christopher S. Hong United States 19 514 0.6× 191 0.2× 240 0.8× 254 0.9× 239 1.4× 89 1.3k
Susanne Burdak‐Rothkamm Germany 18 696 0.8× 324 0.4× 451 1.4× 215 0.8× 67 0.4× 29 1.3k
Jing Cui China 20 412 0.5× 237 0.3× 188 0.6× 253 0.9× 179 1.0× 70 1.2k
Yaping Xu China 19 317 0.4× 411 0.5× 495 1.6× 174 0.6× 233 1.3× 63 1.1k
Maria Christodoulou Greece 19 360 0.4× 335 0.4× 163 0.5× 127 0.5× 247 1.4× 62 1.3k
Hitoshi Niikura Japan 30 673 0.8× 553 0.7× 288 0.9× 233 0.9× 432 2.5× 97 2.5k

Countries citing papers authored by Lye Mun Tho

Since Specialization
Citations

This map shows the geographic impact of Lye Mun Tho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lye Mun Tho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lye Mun Tho more than expected).

Fields of papers citing papers by Lye Mun Tho

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lye Mun Tho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lye Mun Tho. The network helps show where Lye Mun Tho may publish in the future.

Co-authorship network of co-authors of Lye Mun Tho

This figure shows the co-authorship network connecting the top 25 collaborators of Lye Mun Tho. A scholar is included among the top collaborators of Lye Mun Tho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lye Mun Tho. Lye Mun Tho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Poh, Mau Ern, et al.. (2024). Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. Translational Lung Cancer Research. 13(7). 1649–1659. 5 indexed citations
3.
Poh, Mau Ern, Chee-Shee Chai, Chong Kin Liam, et al.. (2024). Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?. Translational Lung Cancer Research. 13(2). 307–320. 2 indexed citations
4.
Tan, Aaron C., D.-W. Kim, Gwo Fuang Ho, et al.. (2023). P2.10-03 Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study. Journal of Thoracic Oncology. 18(11). S352–S353.
5.
Nadal, Ernest, Valentina Guarneri, Marie Wislez, et al.. (2023). 1358P Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC. Annals of Oncology. 34. S780–S781. 1 indexed citations
6.
Poh, Mau Ern, Soon Hin How, Gwo Fuang Ho, et al.. (2023). Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country. Cancer Management and Research. Volume 15. 31–41. 2 indexed citations
7.
How, Soon Hin, Chong Kin Liam, Lye Mun Tho, et al.. (2022). Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia. Cancer Management and Research. Volume 14. 1995–2005. 2 indexed citations
9.
Wu, Yi‐Long, Christophe Dooms, Ernest Nadal, et al.. (2021). 1366TiP Tepotinib + osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2. Annals of Oncology. 32. S1036–S1036. 1 indexed citations
10.
Rajadurai, Pathmanathan, et al.. (2020). Lung Cancer in Malaysia. Journal of Thoracic Oncology. 15(3). 317–323. 24 indexed citations
11.
Tan, Wan Ling, Kevin Lee Min Chua, Chia‐Chi Lin, et al.. (2019). Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. Journal of Thoracic Oncology. 15(3). 324–343. 40 indexed citations
13.
Alip, Adlinda, et al.. (2015). Prognostic Factors in Patients with Non-small Cell Lung Carcinoma and Brain Metastases: a Malaysian Perspective. Asian Pacific Journal of Cancer Prevention. 16(5). 1901–1906. 2 indexed citations
14.
McJury, M., Lye Mun Tho, Derek Grose, et al.. (2013). The influence of MRI scan position on patients with oropharyngeal cancer undergoing radical radiotherapy. Radiation Oncology. 8(1). 129–129. 24 indexed citations
15.
Yusof, Mastura Md, et al.. (2013). Treatment Outcome for Nasopharyngeal Carcinoma in University Malaya Medical Centre from 2004-2008. Asian Pacific Journal of Cancer Prevention. 14(8). 4567–4570. 15 indexed citations
16.
Venugopal, Balaji, et al.. (2013). Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urology. 13(1). 26–26. 13 indexed citations
17.
Carruthers, Ross, et al.. (2012). Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Colorectal Disease. 14(10). e701–7. 123 indexed citations
18.
Tho, Lye Mun, et al.. (2010). The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer. Advances in cancer research. 108. 73–112. 974 indexed citations breakdown →
19.
Tho, Lye Mun, et al.. (2005). Guillain–Barre syndrome occurring after adjuvant chemo-radiotherapy for endometrial cancer. Gynecologic Oncology. 100(3). 615–617. 10 indexed citations
20.
Tho, Lye Mun, Adam D. McIntyre, A H McLean Ross, et al.. (2005). Acute Supraclavicular Skin Toxicity in Patients Undergoing Radiotherapy for Breast Cancer: An Evaluation of the ‘T’-Grip Method of Patient Positioning. Clinical Oncology. 18(2). 133–138. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026